Arvinas, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ARVN Nasdaq 2834 www.arvinas.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arvinas, Inc.

Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains? - Jun 12th, 2026 6:25 am
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data - Jun 5th, 2026 10:10 am
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease - Jun 4th, 2026 6:00 am
Arvinas to Present at Jefferies Global Healthcare Conference - May 29th, 2026 2:01 pm
Arvinas Employees Give Back During Company-wide Impact Day - May 18th, 2026 8:30 am
Bullish: Analysts Just Made A Noticeable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts - May 16th, 2026 7:40 am
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer - May 15th, 2026 2:31 pm
Earnings Beat: Arvinas, Inc. (NASDAQ:ARVN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - May 14th, 2026 6:48 am
Rigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, Arvinas - Has The Bull Case Changed? - May 14th, 2026 12:13 am
These Analysts Increase Their Forecasts On Arvinas After Q1 Results - May 13th, 2026 11:54 am
Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday - May 13th, 2026 7:03 am
Pfizer Shifts VEPPANU Rights To Rigel As Valuation Gap Persists - May 13th, 2026 2:17 am
Arvinas Inc (ARVN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Revenue Decline - May 12th, 2026 1:01 pm
Arvinas Q1 Earnings Call Highlights - May 12th, 2026 8:08 am
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates - May 12th, 2026 6:30 am
Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug - May 12th, 2026 6:05 am
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 12th, 2026 5:05 am
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant) - May 12th, 2026 5:00 am
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer - May 12th, 2026 5:00 am
Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates - May 11th, 2026 3:25 pm